Lupin Liquidating Japan JV With Yoshindo, Partners With I’Rom For Denosumab Biosimilar
Also Receives UK Approval For Lutio Generic Version Of Spiriva
Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.
You may also be interested in...
Alvotech has reported the latest clinical trial results for its AVT03 proposed denosumab biosimilar rival to Prolia and Xgeva.
Samsung Bioepis has reported positive Phase I and Phase III trial results for its SB16 proposed denosumab biosimilar to Prolia.
Amneal has struck a deal with mAbxience to gain US rights to two denosumab biosimilars referencing the Prolia and Xgeva brands that have annual US sales in excess of $4bn.